1263 results about "Cytokine" patented technology

The invention relates to a novel application of animal bifidobacterium subsp. Lactis BGI-N3, in particular to an application of the animal bifidobacterium subsp. Lactis BGI-N3 in preparation of a preparation for relieving skin allergy. The invention finds that the bifidobacterium animalis subsp. Lactis BGI-N3 has a very remarkable effect in the aspect of relieving skin allergy, and the effect is specifically shown as follows: in an atopic dermatitis animal model, the dermatitis score, scratching times and percutaneous water loss are remarkably reduced, and the atopic dermatitis skin tissue damage condition is relieved; the immune organ edema condition is improved, the levels of Th2 type cell factors and inflammatory factors IL-6, TNF-alpha and IFN-gamma related to dermatitis are reduced, and the immune balance of the body is recovered; expression of fibroin and endothelial protein in skin tissue is improved, and the skin barrier is repaired; the level of antibacterial peptide in skin tissues is recovered, and the antibacterial activity of the skin is enhanced. Meanwhile, compared with a traditional chemical medicine for treating atopic dermatitis, the animal bifidobacterium subsp. Lactis BGI-N3 has no side effects such as weight loss, immune organ atrophy, immune imbalance and the like.

The invention relates to the field of medicinal chemistry, and particularly discloses a piperidine derivative as well as a pharmaceutical composition, application and a preparation method thereof. The piperidine derivative has the following general formula. The piperidine derivative can be effectively used for treating or preventing multiple sclerosis, and shows an unexpected synergistic effect in an animal model: the piperidine derivative not only can significantly improve neurological function impairment and promote recovery, but also can deeply reduce the levels of key proinflammatory cytokines IFN-gamma and IL-17 at the same time. The invention provides a novel small molecule candidate drug with central permeability, neuroprotection and comprehensive immune regulation functions for treatment of multiple sclerosis.

The invention provides an adsorbent capable of simultaneously adsorbing bilirubin and cytokines and a preparation method and application thereof, and the preparation method comprises the following steps: carrying out suspension polymerization reaction on a styrene monomer and a polyvinyl cross-linking agent in a dispersion medium under the action of a continuous multi-component pore-foaming agent and an initiator to prepare polystyrene-based macroporous resin; carrying out chloromethylation reaction on the polystyrene-based macroporous resin to prepare chlorine balls; carrying out post-crosslinking reaction on the chloromethylated beads to prepare the adsorbent capable of adsorbing bilirubin and cytokines at the same time; the continuous multi-component pore-foaming agent comprises a first pore-foaming agent, a second pore-foaming agent and a third pore-foaming agent of which the solubility parameters are gradually increased in sequence; the temperature of the suspension polymerization reaction is adjusted according to the mass fraction of the polyvinyl cross-linking agent in the monomer mixture and the solubility parameter of the continuous multi-component pore-foaming agent, and the monomer mixture is composed of styrene monomers and the polyvinyl cross-linking agent. The bilirubin and cell factors can be adsorbed at the same time, and the safety of blood purification is improved.

The invention discloses a cord blood-derived regulatory T cell amplification culture medium and a use method thereof, and relates to the field of animal cell culture and immune cell therapy, the culture medium is a serum-free culture medium, the culture medium is composed of a basic culture medium, a serum substitute combination, a combination of four cell factors, an immunosuppressor, an apparent stabilizer and an antioxidant, and all the components play a role synergistically; according to the use method, cell amplification is realized through a collaborative process of staged environmental regulation and targeted activation. According to the method, the problems of exogenous pollution and batch difference caused by dependence of a serum-containing system on cord blood-derived regulatory T cell amplification in the prior art are solved, the defect that a serum-free scheme is difficult to consider the amplification efficiency and the function stability at the same time is overcome, the cell amplification quality and the clinical application safety are guaranteed, and the method is suitable for large-scale clinical transformation requirements.

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

The invention discloses an SaRNA vaccine for echinococcosis as well as a preparation method and application of the SaRNA vaccine. The preparation method of the SaRNA vaccine comprises the following steps: carrying out codon optimization on a modified target antigen protein through a genetic engineering technology, then assembling the modified target antigen protein with a self-replicating protein sequence, 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a plasmid, and carrying out purification to obtain the SaRNA vaccine. The preparation method comprises the following steps: constructing recombinant plasmids, sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmids to prepare SaRNA molecules, and finally wrapping the SaRNA molecules in lipid nanoparticles to form the SaRNA vaccine for the echinococcosis. Experiments prove that the SaRNA vaccine can activate humoral immunity and cellular immunity of mice at the same time, high-level EG95 specific antibodies and cytokines can be generated through low-dose immunity, and the SaRNA vaccine has wide application prospects in the aspect of preventing and / or treating the echinococcosis.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating triple negative breast cancer and application thereof. The traditional Chinese medicine composition is prepared from the following main active ingredients in parts by mass: 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of rhizoma curcumae, 10 to 20 parts of herba hedyotidis diffusae, 5 to 15 parts of fructus aurantii immaturus, 5 to 15 parts of radix bupleuri, 5 to 15 parts of radix paeoniae alba and 5 to 15 parts of liquorice root. Animal experiments show that the traditional Chinese medicine composition can significantly inhibit tumor growth and pulmonary metastasis of triple-negative breast cancer tumor-bearing mice, increase the proportion of CD8 + T lymphocytes in blood, reduce the proportion of MDSCs, significantly down-regulate the expression of pro-inflammatory cytokines such as IL-6, IL-1alpha, CXCL1 and GM-CSF in serum, and cooperate with PD-L1 immunotherapy to achieve a synergistic effect. And the whole blood and liver and kidney function indexes are in a normal range. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively inhibiting the tumor growth and pulmonary metastasis of the triple negative breast cancer, remodeling the immune state of an organism and reducing the release of proinflammatory factors, and is safe, reliable, free of obvious liver and kidney toxicity and blood toxicity and small in side effect.

An antigen peptide is provided specifically for treating individuals suffering from ovarian cancer, preferably based on BRCA1 gene c. 5470_5477del8 mutation. It is selected from amino acid sequences of SEQ ID NO. 1 to SEQ ID NO. 6, or derived by substitution, deletion and / or addition of at least one amino acid. The neoantigen polypeptides of the present disclosure can significantly activate T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro, stimulating the release of the cytokine IFN-y, indicating notable immunogenicity. This enhances T lymphocytes' ability to target and kill cancer cells from ovarian cancer patients carrying the BRCA1 gene c. 5470_5477del8 mutation. Additionally, the antigen peptide can activate and expand human T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro for adoptive cell therapy. The antigen peptide of the present disclosure addresses the gap in personalized antigen peptide therapies for ovarian cancer patients with BRCAl-c. 5470_5477del8 somatic mutations.

The invention relates to artificial skin, in particular to self-generating full-layer artificial skin for wound treatment and application of the self-generating full-layer artificial skin. The artificial epidermis has an epidermis-dermis structure similar to skin, and the artificial epidermis structure is composed of an electrostatic spinning nano-film with piezoelectric capacity and has the functions of sterilization, protection and bioelectricity generation of an epidermis layer; the artificial dermal structure is composed of a photo-crosslinking polysaccharide and enzyme crosslinking protein interpenetrating hydrogel skeleton, by adding bioactive components and loading living cells, the effects of releasing active components and cytokines, remodeling wound extracellular matrix and promoting cell proliferation are achieved, and finally healing of acute and chronic wounds is remarkably accelerated. The invention provides a simple, feasible, economical and effective treatment method for sealing a large-area wound, sterilizing the wound and promoting healing of the wound.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention belongs to the technical field of biological medicines, and discloses a traditional Chinese medicine composition for treating microsatellite stability (MSS) type tumors by a sensitization immune checkpoint inhibitor. The traditional Chinese medicine composition provided by the invention comprises radix scutellariae, rhizoma zingiberis, Chinese herbaceous peony, liquorice root and Chinese date, can increase CD8 + T cell infiltration, promote the CD8 + T cell to secrete cytokines and improve the immunosuppression of MSS type tumors, and further breaks through the conventional range of anti-tumor treatment of immune examination inhibitors; meanwhile, the traditional Chinese medicine composition can also improve adverse reaction of gastrointestinal tracts caused by tumor treatment by an immune examination inhibitor, and the life quality of patients is improved.

The present invention relates to antibody-cytokine conjugates, wherein the cytokine is conjugated to the antibody via a cleavable linker. Conjugates according to the invention can be prepared by coupling a functionalized antibody Ab (F) x comprising x reactive moieties F, where x is an integer in the range of 1-10, with an immune cell-binding polypeptide comprising one or two reactive moieties Q, where the antibody is specific for tumor cells, and the immune cell-binding polypeptide is specific for immune cells, wherein the reaction forms a covalent bond between the functionalized antibody and the immune cell-binding polypeptide by reaction of Q with F. The invention further relates to antibody-cytokine conjugates obtainable by the method according to the invention and to medical uses thereof.

The invention relates to proximity activated cytokine compounds comprising a PD-1 targeting moiety, and an IL-21 polypeptide covalently linked to an anti-IL-21 antibody-binding domain, which together provide targeted cytokine signaling to PD-1 expressing cells. The invention further relates to nucleic acid and expression vectors encoding proximity activated cytokines, as well as use of such compounds for treating cancer.

The invention discloses an adipose-derived stem cell exosome compound loaded with silver nanoparticles and application of the adipose-derived stem cell exosome compound loaded with the silver nanoparticles, and ADSC-Exos loaded with the silver nanoparticles is developed by integrating AgNPs into an exosome of ADSCs. In vivo, the Exo-AgNPs can accelerate healing of infected wounds by reducing bacterial colonization and promoting collagen deposition, angiogenesis and M2 type macrophage polarization. In vitro, the Exo-AgNPs activates the functions of fibroblasts and vascular endothelial cells, and shows an excellent antibacterial property. In addition, the Exo-AgNPs induces polarization of M2 type macrophages and inhibits secretion of proinflammatory cytokines by activating autophagy. The results show that Exo-AgNPs is expected to become an ideal biological material for treating infected wounds.

The invention belongs to the technical field of biological detection, and provides a multiple cell factor detection kit in tumor immunity and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture antibody is prepared by coupling a biotinylated antibody with a fluorescent microsphere coated with biotin to obtain a capture antibody coupled with a fluorescent encoding microsphere, and the detection antibody is prepared by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody to obtain a fluorescent labeled antibody; the mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect various cell factors, the sample dosage is only 25 microliters, the kit is suitable for immune monitoring of iron overload and other chronic inflammation models, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of being high in throughput, wide in linear range and high in stability.

A Bifidobacterium longum subsp. longum dipro-017. The Bifidobacterium longum subsp. longum dipro-017 used has the ability to metabolize tryptophan to produce indole-3-lactic acid, can inhibit the pathogenic bacteria Salmonella Typhimurium, Staphylococcus aureus, and Escherichia coli, and can effectively mitigate weight loss caused by ulcerative colitis, improve a DAI score, improve colon length, mitigate the content of lipopolysaccharide (LPS) in blood, and increase the level of anti-inflammatory cytokine IL-10, as well as mitigate the content of bone metabolism indicators tartrate-resistant acid phosphatase (TRAP) and N-terminal propeptide of type I procollagen (PINP) in blood.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can reduce the levels of MDA and NO in serum of mice and improve the activity of SOD and CAT and the content of GSH so as to relieve oxidative stress injury; inflammatory cell infiltration of nasal mucosa is reduced, and lung tissue inflammatory mediator level and inflammation-related gene expression are reduced to inhibit inflammation; th1 / Th2 immune balance is regulated, Th2 type cytokines are reduced, Th1 type cytokines are increased, and the high-dosage effect is close to that of loratadine. The strain has a treatment effect on allergic rhinitis through multiple mechanisms, and a new choice is provided for treatment of the strain.

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

To provide IL2 engrafted into CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic.SOLUTION: An antibody cytokine engrafted protein comprises: (a) an IgG class heavy chain comprising an IgG class heavy chain variable region (VH), comprising Complementarity Determining Regions (CDR) HCDR1, HCDR2, HCDR3, wherein HCDR comprises 0-1 substitution; (b) an IgG class light chain comprising an IgG class light chain variable region (VL), comprising LCDR1, LCDR2, LCDR3, wherein LCDR comprises 0-1 substitution; and (c) a mutated Interleukin 2 (IL2) molecule engrafted into HCDR1, wherein the mutated IL2 molecule comprises mutations that reduce affinity of the mutated IL2 molecule for a high-affinity IL2 receptor.SELECTED DRAWING: None

The present disclosure relates to a CCL20 promoter derived from a regulatory region of the CCL20 gene, which stimulates gene expression in response to inflammation. These CCL20 promoters, which can be stimulated by endogenous or exogenous cytokines, can be used to control the timing of expression of heterologous genes. The disclosure also relates to expression cassettes or vectors comprising a CCL20 promoter of the disclosure operably linked to a nucleic acid sequence encoding, for example, a polypeptide of interest; and delivery systems (e.g., viral particles, lipid vesicles or nanoparticles) or cells comprising such expression cassettes or vectors. The disclosure also relates to the use of the promoter, expression cassette, vector, delivery system or cell in the treatment of inflammation-related diseases or for recombinant gene expression.

The invention relates to the technical field of microorganisms, in particular to an anti-inflammatory compound probiotic and application thereof.Lactobacillus rhamnosus LGD-0817, lactobacillus rhamnosus LDL-1708 and lactobacillus plantarum LEP-1208 serve as basic dominant bacteria and then are compounded with multiple bacteria such as lactobacillus casei, lactobacillus delbrueckii and lactobacillus paracasei, the multiple bacteria can be matched and promoted mutually, and the anti-inflammatory compound probiotic has the anti-inflammatory effect. The traditional Chinese medicines jointly play a significant role in improving ulcerative colitis; the anti-inflammatory compound probiotics are used for traditional Chinese medicine fermentation, and the obtained traditional Chinese medicine fermentation composition can regulate intestinal flora, enhance the barrier function of the intestinal tract, inhibit release of proinflammatory factors, improve the shortening of the colon length of a mouse with colitis, inhibit the levels of proinflammatory cytokines IL-1beta, IL-6 and TNF-alpha, competitively inhibit colonization of pathogenic bacteria and improve the colonization of colitis. The method shows a good comprehensive intervention effect in a DSS-induced mouse ulcerative colitis model, and has clinical practical value.

The invention belongs to the technical field of biological detection, and provides a multiple cell factor detection kit in macrophage polarization and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture system is used for preparing a capture antibody coupled with a fluorescence coding microsphere by coupling a biotinylated antibody with a fluorescence microsphere coated with biotin, and the detection system is used for preparing a fluorescence labeled antibody by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody. The mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect multiple cell factors, the sample dosage is only 25 microliters, the kit is suitable for in-vitro tests of mouse mononuclear macrophage leukemia cell lines RAW264.7, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of being high in throughput, wide in linear range and high in stability.

The invention discloses a novel immunologic adjuvant, a composition containing the immunologic adjuvant and a pharmaceutical composition. The immunologic adjuvant is picrasidine S. The immunologic adjuvant composition comprises picrasidine S and optionally one or more other types of immunologic adjuvants, such as an aluminum adjuvant. The pharmaceutical composition comprises an antigen and the immunologic adjuvant composition. Experiments prove that the picrasidine S can effectively stimulate dendritic cells to generate cell factors IFN-beta and IL-6, and has PS dose dependence; picrasidine S plays an important role in enhancing specific humoral immune response of different types of antigens, and has a stronger effect than an aluminum adjuvant; the picrasidine S immunity can enhance the anti-tumor immune response in different tumor models. According to the invention, a new candidate drug is provided for research and development of a new generation of vaccine adjuvants, and meanwhile, the medical application of the picrasidine S is also widened.

The invention belongs to the field of daily chemicals, and particularly relates to a body cleaning composition containing folium artemisiae argyi extract and a preparation method of the body cleaning composition. 14%-20% of a surfactant; 0.5-5% of a skin conditioner; 0.01%-0.1% of a metal chelating agent; 0.01%-1.2% of a preservative; 0.01%-1% of a pH regulator; 1 to 1.5 percent of flavoring agent; 0.01%-1% of a viscosity modifier; and the balance of deionized water. The plant functional composition comprises a folium artemisiae argyi extract and a rosa canina fruit extract. The folium artemisiae argyi extract and the rosa canina fruit extract in the composition can achieve a synergistic effect, free radicals can be effectively removed, release of cell factors and inflammatory mediators can be inhibited, and the composition has anti-inflammatory and soothing effects, can relieve uncomfortable symptoms such as skin redness and itching and has a certain whitening effect.

The invention provides a dynamic regulation and control method for optimizing CAR-T cell amplification conditions, which comprises the following steps: acquiring high-frequency cell activity monitoring data from a cell culture system, and extracting metabolic marker fluctuation and proliferation rate mutation from the high-frequency cell activity monitoring data to obtain real-time cell state parameters; comparing the real-time cell state parameters with a T cell subset proportion and a cell factor release mode in historical immune data of the patient to obtain a cell state deviation value, and determining an abnormal fluctuation condition of proliferation rate mutation according to the cell state deviation value; if the abnormal fluctuation of the proliferation rate mutation exceeds a preset fluctuation threshold value, capturing proliferation signal abnormity by analyzing metabolic marker fluctuation and metabolic waste accumulation according to the cell state deviation value; according to the targeted culture parameter set, adjusting the oxygen supply quantity and the culture solution microenvironment of an oxygen concentration control system to obtain a culture environment for inhibiting cytokine storm and proliferation signal abnormity.

The preparation method comprises the following steps: by taking an oriented polylactic acid nanofiber membrane as a raw material, carrying out homogenization treatment to obtain polylactic acid piezoelectric short fibers; gelMA is used as a skeleton matrix, polylactic acid short fibers, LAP and DRG cells are compounded, a 0 / 90-degree alternate grid structure scaffold is constructed through pneumatic extrusion type biological printing, and the dual-network piezoelectric biological scaffold is formed through blue light crosslinking curing. The piezoelectric effect of polylactic acid short fibers is activated through ultrasonic stimulation, mechanical energy is converted into local electric signals, loaded DRG cells are directly driven to secrete CGRP in situ, macrophages are dynamically regulated and controlled to be polarized to M2 anti-inflammatory phenotypes, nerve-immune microenvironment disorder of diabetic bone defects is corrected, vascularization and bone regeneration are promoted, and the diabetic bone defect treatment effect is improved. The problems of short delivery half-life period of traditional cell factors, difficulty in nerve function reconstruction and chronic inflammation caused by non-degradable piezoelectric materials are solved, and non-invasive and degradable precise bone repair is realized.

Provided are a postbiotic of Weizmannia coagulans, and a preparation method therefor, and a use thereof. The postbiotic comprises inactivated bacteria and / or lipoteichoic acid. The postbiotic can enhance the phagocytosis activity of macrophages, the cytokine and NO secretion ability of macrophages, and the expression levels of immune-function-related genes and proteins, and has an effect of inducing human PBMC cells to kill cancer cells.

The invention discloses an exosome as well as a preparation method and application thereof, and relates to the field of biological medicines. The mesenchymal stem cells and the immune cells are co-cultured, the immunomodulatory cell factor IL-2 and the mTOR inhibitor are added, the exosome in the co-culture supernatant is extracted and applied to wound injury repair, wound healing can be effectively improved, and a better repair effect is achieved. Meanwhile, the exosome also has better effects of removing oil, preserving moisture, fading spots, whitening, resisting wrinkles, shrinking pores and increasing elasticity, and can effectively promote skin recovery.

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.